Offshoring-Good opportunity to Indian pharma cos: BCG report

Bangalore, Sep 12 (UNI) Offshoring to India and China by the bio-pharmaceutical industry is catching up, with the regulatory and competitive environment in both countries improving.

This was stated by 'Looking Eastward', a report, which explored the opportunities offered by India and China to reinvigorate the global bio-pharma industry, was released by the Boston Consulting Group (BCG) here today.

As threats to their profitability loom, multinational pharma companies were increasingly looking at offshoring research and development (R and D) to the two countries to help them increase productivity and reduce costs, after the industry had historically lagged behind in hopping on to the offshoring bandwagon, the report said.

Speaking at the launch, BCG in India Director Paresh Vaish said ''this trend creates a very substantial opportunity for Indian pharma. Indian pharma companies are well positioned to generate real and fast value for global pharma players by taking on contract, research and clinical trial work. India now needs to take advantage of this situation with greater investments in equipment and manpower to maintain its lead in chemistry and data management activities and narrow the gap in biology-related work.'' India held out great opportunity to meet the R and D productivity challenge. While many R and D activities currently offshored to India had been launched and managed in an ad hoc fashion, those companies that carefully implement a more integrated and deliberate strategy would have the greatest advantage in the future, the report said.

UNI RS GD SBA VV1801